Literature DB >> 1970852

Treatment of positive and negative symptoms: pharmacologic approaches.

P Boyer1, Y Lecrubier, A J Puech.   

Abstract

Mesh:

Substances:

Year:  1990        PMID: 1970852     DOI: 10.1159/000418016

Source DB:  PubMed          Journal:  Mod Probl Pharmacopsychiatry        ISSN: 0077-0094


× No keyword cloud information.
  7 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

Authors:  J L Martinot; M L Paillère-Martinot; M F Poirier; M H Dao-Castellana; C Loc'h; B Mazière
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Risperidone versus placebo for schizophrenia.

Authors:  Ranganath D Rattehalli; Sai Zhao; Bao Guo Li; Mahesh B Jayaram; Jun Xia; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

Review 4.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 5.  Amisulpride for schizophrenia.

Authors:  N E Mota; M S Lima; B G Soares
Journal:  Cochrane Database Syst Rev       Date:  2002

6.  Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia.

Authors:  Y Noda; K Yamada; H Furukawa; T Nabeshima
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

Review 7.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie J Sampson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.